Articles tagged with Multiple Sclerosis
A multidisciplinary panel recommends careful, well-designed research on chronic cerebrospinal venous insufficiency (CCSVI) in multiple sclerosis patients. The goal is to evaluate the role of vein widening with angioplasty and potential stent placement in improving symptoms.
A study at The University of Nottingham found that group therapy sessions can reduce anxiety and depression in MS patients, improving their quality of life. The treatment reduced costs for the NHS by almost £470 per patient, with savings also seen in GP visits and outpatient hospital costs.
Researchers have found that shingles may be associated with an increased risk of developing multiple sclerosis, particularly in the year following a shingles attack. The study suggests that this risk is still relatively low and varies by geographical location and income.
Researchers at UCI have identified a unifying mechanism responsible for multiple sclerosis, suggesting personalized therapies based on genetic factors. Vitamin D3 and GlcNAc supplements can reverse the effects of four human MS genetic factors, restoring normal protein modification and potentially treating the disease.
A recent study published in Neurology found that stress does not increase the risk of developing multiple sclerosis. Researchers studied two groups of nurses and found no significant link between severe stress at home or during childhood and adolescence and the development of MS.
African Americans with multiple sclerosis have lower vitamin D levels than those without the disease. The study suggests low vitamin D may be a risk factor for developing multiple sclerosis, but other factors such as genes and environmental triggers also play a role in disease severity.
Researchers at UC Santa Barbara developed a new method of nanoscopic imaging that could lead to early detection and diagnosis of multiple sclerosis. The study focused on the myelin sheath, a membrane surrounding nerves compromised in MS patients.
Vitamin D deficiency is prevalent among African-American patients with MS, largely due to regional UV exposure and geographic factors. Low vitamin D levels were found in nearly 77% of MS patients compared to 71% without the disease.
Researchers discovered that Viagra reduces multiple sclerosis symptoms by reducing inflammation and facilitating myelin repair. A daily treatment resulted in a 50% practically complete recovery rate in animal models with the disease.
Researchers at University of Granada analyzed antibody levels in patients with multiple sclerosis and found a statistically significant association between viral infection markers and the condition. Further research is needed to confirm the link.
Researchers discovered that estrogen receptors in the brain help turn off genes leading to chronic inflammation. This finding may lead to new treatments for multiple sclerosis and other neurodegenerative conditions.
Researchers have created a new X-ray method called SAXS-CT to map the myelin sheaths of nerve cells in detail. This can provide insights into neurodegenerative diseases such as cerebral malaria, multiple sclerosis, and Alzheimer's disease.
A paper in Nature notes the power of social media in shaping research priorities in Canada, particularly in the case of a controversial multiple sclerosis treatment. Researchers call for more effective communication tools between scientists and the public to ensure patients' concerns are heard.
Researchers have identified GM-CSF as a driving force behind autoimmune diseases like MS. Blocking its activity may lead to new treatments for the disease. Dr. Abdolmohamad Rostami and his team found that GM-CSF is responsible for disease manifestation in an experimental animal model.
Researchers found GM-CSF crucial for MS disease progression, neutralizing it could reverse inflammation. A clinical trial is set to launch this year to test GM-CSF neutralization in patients.
Researchers found a strong association between low sunlight exposure and an increased risk of developing multiple sclerosis (MS) in people who have had infectious mononucleosis. The study, published in the April 2011 issue of Neurology, suggests that vitamin D deficiency may play a role in this association.
A newly developed compound, SR1001, has been shown to effectively suppress the severity of multiple sclerosis in animal models with minimal side effects. The discovery holds promise for treating other autoimmune diseases and targets a specific cell type involved in autoimmunity.
Researchers found that a subgroup of PPMS patients can convert to PRMS, with faster disease progression and increased risk for sustained disability. The study emphasizes the need for clinicians to consider evaluating this subgroup differently in assessing prognosis and clinical course.
A recent study found that chronic cerebral venous insufficiency (CCSVI) is more prevalent in multiple sclerosis (MS) patients, particularly those with progressive forms of the disease. The research suggests CCSVI may be a consequence of MS progression rather than a cause, warranting further investigation.
Researchers at Mayo Clinic have created a tool that uses cerebrospinal fluid test results to predict disability timelines for patients with progressive multiple sclerosis. The study found that patients with higher levels of certain proteins in their CSF are more likely to experience a faster onset of disability.
A Phase III clinical study found that laquinimod reduced annual relapse rates by 23% and disability progression by 36%. Laquinimod also slowed brain atrophy by 33%. The study involved 1,106 people with relapsing-remitting MS in 24 countries.
Researchers found that people who used marijuana performed significantly worse in attention, speed of thinking, executive function, and visual perception, with some scoring approximately one third lower than non-users. The study suggests that prolonged marijuana use may add to the cognitive burden already experienced by MS patients.
Researchers have shown that angioplasty to widen internal jugular and azygos veins is safe for multiple sclerosis patients. The treatment improved blood flow and reduced symptoms in 97% of patients with no significant complications.
Scientists have discovered a previously unknown type of axonal degeneration called focal axonal degeneration (FAD), which is responsible for damage to nerve cells in multiple sclerosis. FAD can be reversed if recognized and treated early, suggesting a potential target for therapeutic intervention.
A long-term study reports the effectiveness of stem cell transplants in replacing bone marrow and reducing disease activity in people with rapidly progressive MS. The treatment showed promising results, with an average improvement in symptoms lasting two years.
A study published in Neurology has found that children with a specific gene variation are at higher risk of developing Multiple Sclerosis. The research identifies the HLA-DRB1 allele as a key factor in pediatric-onset MS, which can provide insights into disease causes and potentially lead to earlier diagnoses and new therapies.
The revised McDonald Criteria simplify the diagnostic process by incorporating new data on MRI, speeding up diagnosis while maintaining accuracy. The updated criteria apply primarily to individuals with clinically isolated syndrome or symptoms consistent with a central nervous system inflammatory demyelinating disease.
Researchers found a delay in detecting CADASIL, a vascular brain disorder, and diagnosed it as multiple sclerosis in some patients. The study suggests that CADASIL often goes misdiagnosed due to similarities with MS in brain MRIs and symptoms.
Researchers at Ruhr-University Bochum have found that fumaric acid salts exhibit neuroprotective effects in Multiple Sclerosis by detoxifying radicals and supporting nerve cell survival. This discovery offers new hope for treating MS, potentially combining with existing medications.
Researchers from Washington University School of Medicine successfully blocked harmful immune cells from entering the brain in mice with a condition similar to multiple sclerosis. The breakthrough discovery, made using an anti-cancer drug, prevents symptoms and provides early evidence for a potential new treatment.
New research suggests that increasing vitamin D3 supplies through sunlight exposure may be a safe and effective therapy for Multiple Sclerosis (MS). Studies found that patients with the highest vitamin D3 supplies experienced fewer attacks and slower disease progression.
Researchers at Wayne State University found that targeting white blood cells known as T cells is effective in blocking the disease in an animal model of MS. This study resolves a long-disputed issue and provides a valid therapeutic approach for the most common form of multiple sclerosis.
Research found that individuals with MS performed better on learning and memory tests during cooler days compared to warmer days. The study suggests a link between warm weather and cognitive impairment in people with MS, which could inform life decisions and clinical treatment.
Damage to a specific area of the brain and decreased noradrenaline levels are linked to multiple sclerosis progression. The study found that noradrenaline plays a crucial role in preventing inflammation and preserving blood-brain barrier integrity.
A study published in Neurology found that people with higher sun exposure and vitamin D levels were less likely to develop multiple sclerosis. The researchers also discovered that increased UV light exposure and skin damage from sun exposure reduced the risk of developing the disease.
New research suggests histamine plays a critical role in preventing or lessening the effects of multiple sclerosis. Histamine reduces MS-causing T cell proliferation and interferon-gamma production, and its ability to adhere to brain vessels.
The American Academy of Neurology recommends using plasma exchange to treat people with severe relapses in multiple sclerosis (MS) and related diseases, as well as those with certain kinds of nerve disorders known as neuropathies. Plasma exchange has been found effective for treating severe flares in relapsing forms of MS.
Researchers have discovered a new factor in multiple sclerosis (MS) that can serve as a potential target for therapeutics. The study found that inhibiting the molecular switch EMMPRIN reduces MS-like symptoms in mice.
A study of over 2,100 individuals with multiple sclerosis found that women were 1.4 times more likely to carry the HLA gene variant associated with MS than men. The researchers also discovered that women with this gene variant were more likely to pass it on to other women in their families.
A new study published in the Journal of Lipid Research found that oxysterols, previously thought to be associated with multiple sclerosis, are not present in significant amounts in MS patients. The research contradicts a previous study and suggests the potential role of oxysterols in MS needs reconsideration.
Researchers have identified a mechanism to regenerate insulating layers in the brain that protect nerve fibers in multiple sclerosis. The study shows activating stem cells can repair injury in the central nervous system, reversing damage caused by MS.
A new tool has been developed to measure the quality of patient care for people with brain disorders, including Parkinson's disease. The tool evaluates non-motor symptoms, diagnosis and treatment, safety, and more, providing a comprehensive assessment of care.
The American Academy of Neurology has developed a new quality measures tool to help doctors gauge how well they are caring for people with Parkinson's disease, focusing on non-motor symptoms such as depression and falls. The measures aim to improve the quality of care for individuals with neurologic disorders like Parkinson's disease.
Researchers at Purdue University have found evidence that acrolein, an environmental toxin, may play a key role in causing multiple sclerosis. They also discovered that the hypertension drug hydralazine can delay disease onset and reduce symptoms by neutralizing acrolein.
A new compound, ATL313, has shown promise in reversing multiple sclerosis (MS) effects by resetting glial cells to an anti-inflammatory state. The treatment stopped MS-caused paralysis in rats for weeks at a time and could potentially heal lesions, offering a major breakthrough in treating MS symptoms.
Scientists have discovered two new compounds that show promise as treatments for botulism poisoning, building on a multiple sclerosis drug. The compounds did not enter the brain and showed good potential in mice paralyzed by the toxin.
A study of 28 pregnant women with MS found that lower vitamin D levels during pregnancy and breastfeeding were not associated with an increased risk of relapse after childbirth. However, women who breastfed exclusively had lower postpartum vitamin D levels, which may be related to the duration of breastfeeding rather than a causal link.
Recent studies have identified 20 genes associated with multiple sclerosis susceptibility, paving the way for more accurate understanding of the disease. New therapies targeting neuroinflammation and regenerative stem cells hold promise for controlling the disease, mirroring progress made in AIDS treatment.
Stereotactic radiation is a proven alternative to surgery or anti-epileptic drugs for treating trigeminal neuralgia in MS patients. The study shows that radiosurgery using Gamma Knife is highly effective in reducing pain and improving quality of life for those affected.
Researchers found a previously unknown link between two ion channels that can cause symptoms in MS patients. The sodium and leak current channels play a crucial role in signal transmission, and manipulating their balance may lead to new therapeutic opportunities.
Research led by Dr. Fu-Dong Shi at Barrow Neurological Institute revealed that natural killer cells play a critical role in controlling CNS inflammation and immune response. Enriching affected areas with NK cells improved disease symptoms, while blocking them worsened outcomes.
A study found that mindfulness meditation training reduced fatigue and depression in people with mild to moderate multiple sclerosis, improving overall quality of life. The positive effects continued for at least six months.
A new study reveals that immune cells directly interact with and damage neurons in multiple sclerosis, leading to inflammation and neuronal injury. The findings suggest a potential therapeutic target for treating the incurable disease, by modulating calcium levels within neurons.
Researchers explore how genetic variations interact with environmental factors like nicotine, vitamin D, and EBV to accelerate multiple sclerosis progression. The two-year project aims to identify gene-environmental interactions that can inform preventive and therapeutic strategies.
Adding albuterol to a treatment for multiple sclerosis improves functional status and reduces inflammation by decreasing interleukin-12 levels. The study suggests that combining glatiramer acetate with albuterol is well-tolerated and enhances clinical response in patients with relapsing-remitting MS.
A £10 million donation from JK Rowling has led to the establishment of a research clinic focused on patient-based studies for multiple sclerosis. The clinic will explore treatments to slow disease progression, with potential implications for other degenerative neurological conditions.
A study found that multiple sclerosis lesions appeared two to three times higher in spring and summer months compared to other seasons. Warmer temperatures and solar radiation were linked to increased disease activity.
The Society of Interventional Radiology supports high-quality clinical research to determine the safety and effectiveness of interventional M.S. treatments for vulnerable patients. SIR aims to catalyze the development of needed studies, prioritizing individualized assessments and scientific plausibility.
Research reveals vitamin D's impact on multiple sclerosis, rheumatoid arthritis, type 1 diabetes, cancers, and dementia. The study identified 2,776 binding sites for the vitamin D receptor across the genome.
Researchers discovered the function of PTP-PEST, a protein that stimulates T cells' participation in immune responses, potentially leading to new treatments for autoimmune diseases. The study's results suggest that suppressing PTP-PEST could prevent certain autoimmune diseases and weaken overactive immune responses.